Despite the transformative potential of GLP-1 medications like Ozempic, Wegovy, and Zepbound in treating obesity as a disease, users are encountering significant social stigma. These drugs were anticipated to shift the perception of weight from a moral failing to a complex medical condition. However, the broader American culture has not fully embraced this view, and individuals using GLP-1s for weight loss are facing criticism and shaming.
Social media communities and personal anecdotes reveal widespread instances of judgment. Partners have berated significant others considering the medications, coworkers have blamed GLP-1 users for rising insurance costs, and even healthcare professionals have been dismissive. Many users feel they are navigating a hostile environment, overhearing negative comments about perceived "shortcuts" to weight loss.
Research supports these experiences. A study led by Erin Standen, a psychology professor at Rice University, found that participants held more negative views toward individuals who lost weight using GLP-1s compared to those who lost weight through diet and exercise. Alarmingly, participants even viewed GLP-1 users more negatively than individuals who had not lost weight at all. "People are really reacting negatively to the idea that somebody who has lost weight with a GLP-1 might be, quote-unquote, ‘taking the easy way out’ or cheating the system," Standen explained.
This reaction is attributed to deeply ingrained cultural beliefs that equate being overweight with personal failure. Susan Persky, a behavioral scientist at the National Institutes of Health, notes that when weight management is perceived as solely a matter of willpower and hard work, GLP-1s are often seen as a "cheat or a hack." This can lead to individuals who use these medications being perceived not only as lazy but also as having bypassed the effort others have supposedly "earned" through traditional means.
Personal Experiences with Stigma
Individuals like Adriana, a 33-year-old GLP-1 user from Chicago, and Mike, 50, from the Boston area, have shared their struggles with stigma. Adriana experienced weight gain due to a mental health episode and sought medical intervention to avoid further health complications. Despite the positive impact of the medication on her well-being, she has faced judgment, with some in her life complimenting her appearance while simultaneously criticizing others for using weight-loss drugs.
Mike, who lost approximately 170 pounds with the help of Zepbound after struggling with his weight his entire life, encountered judgment from his friend's mother who scrutinized his eating habits throughout a weekend visit. He initially believed the medication was a positive development that should be openly shared but realized the social backlash made it difficult to discuss.
"It was eye-opening because when I first went on it, I’m like, ‘I don’t understand why people don’t want to tell anybody. This is a good thing. The world should know,’" Mike recounted. "And then you realize, ‘Oh, God, this is affecting my ability to enjoy myself this weekend because I have to answer for it every two seconds.'"
Consequences of Stigma
The consequences of this stigma extend beyond strained personal relationships. Experiencing shame and stress from perceived judgment can negatively impact an individual's physical and mental health. Researchers like Standen highlight that these instances of discrimination can accumulate, directly harming overall well-being. Furthermore, fear of judgment may lead individuals to avoid healthcare or be less forthcoming with providers, potentially jeopardizing their long-term health.
Evolving Attitudes and Future Outlook
As the use of GLP-1 medications continues to expand, there are indications that the associated stigma may lessen. Increased prevalence means more people will either use these drugs or know someone who does, potentially fostering more understanding. Data from PricewaterhouseCoopers indicates a growing number of households with GLP-1 users, and Medicare's recent $50 prescription program is expected to further broaden access.
"As these medications become more prevalent and more people have either used them themselves or have a close loved one who has used them, it is possible that that will help to reduce the stigma and increase acceptance," Standen stated. Social psychology research suggests that increased contact with unfamiliar identities or situations tends to reduce bias over time.
While attitudes may still be evolving, there are signs of increasing openness. A significant percentage of current GLP-1 users openly discuss their use, and those considering the medications are even more inclined to share. This trend suggests a gradual shift in social perception, potentially making GLP-1s a more accepted part of obesity treatment in the future.